Nitrofurantoin is a nitrofuran or urinary antibacterial agent specific for urinary tract infections. It is highly effective for UTIs because the body quickly filters the medicine out of the blood and concentrates it in the urine, targeting the site of infection directly.
Nitrofurantoin is highly soluble in urine and there it inactivates or alters bacterial ribosomal proteins and inhibit bacterial enzymes involved in the synthesis of DNA, RNA, cell wall protein synthesis and other metabolic enzymes.
Utifin SR Capsule: Each capsule contains Nitrofurantoin USP 100 mg.
Nitrofurantoin is specifically indicated for the treatment & prophylaxis of urinary tract infections caused by susceptible strains of Escherichia coli, Enterococci, Staphylococcus aureus, Staphylococcus saprophyticus and certain susceptible strains of Klebsiella and Enterobacter species.
Nitrofurantoin capsule should be taken with food.
Adults and Children over 12 years: One 100 mg capsule every 12 hours for seven days.
Genito-urinary surgical prophylaxis: One 100 mg capsule twice daily on day of procedure and for next 3 days.
Anuria, oliguria or significant impairment of renal function (creatinine clearance under 60 ml/minute) are contraindications. Because of the possibility of hemolytic anemia due to immature erythrocyte enzyme systems (glutathione instability) the drug is contraindicated in pregnant patients at 38-42 weeks, during labor and delivery. Nitrofurantoin is also contraindicated in those patients with known hypersensitivity to Nitrofurantoin.
If acute, sub-acute, or chronic pulmonary reactions occur, Nitrofurantoin should be discontinued. Antacid preparations containing magnesium trisilicate should not be taken while taking Nitrofurantoin.
The most frequent clinical adverse events are nausea, headache, and flatulence. Other less occurred adverse events are diarrhea, dyspepsia, abdominal pain, constipation, emesis, dizziness and drowsiness.
Antacids containing magnesium trisilicate, when administered concomitantly with Nitrofurantoin, reduce both the rate and extent of absorption. Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of Nitrofurantoin.
Pregnancy: Safe in pregnancy. There are no adequate and wall-controlled studies in pregnant woman. This drug should be used during pregnancy only if clearly needed.
Lactation: Nitrofurantoin has been detected in human breast milk in trace amounts. Because of the potential for serious adverse reactions from Nitrofurantoin in nursing infants under one month of age, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Use in the elderly: The greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy in elderly patients should be considered when prescribing Nitrofurantoin.
Use in pediatric population: Nitrofurantoin is contraindicated in infants below the age of one month. Safety and effectiveness in pediatric patients below the age of 12 years have not been established.
Utifin SR Capsule: Each box contains 20 Capsule in alu-alu blister pack.
FR
DE